Results 151 to 160 of about 22,889 (244)

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma. [PDF]

Sci Adv
Han JZR, Phimmachanh M, Hastings JF, Leong KH, Ng BH, Ni J, Fontaine-Titley A, Cadell AL, O'Donnell YE, Clearwater M, Kamili A, Haber M, Norris M, Timpson P, Trahair TN, Fletcher JI, Fey D, Kolch W, Latham SL, Croucher DR.   +19 more
europepmc   +1 more source

Résistance cellulaire au Topotecan

Il a été démontré dans plusieurs modèles expérimentaux que le niveau cellulaire de la topoisomérase I corrèle avec la sensibilité des cellules aux dérivés de la camptothécine, tel que le topotecan. Cependant, malgré l'intérêt clinique de ces drogues dans
St-Amant, Christiane
core  

Quantitative high-throughput screening identifies small-molecule modulators of Wnt/β-catenin signaling. [PDF]

Front Pharmacol
Chen X, Yang S, Sakamuru S, Sukhawanit C, Wood S, Ooka M, Huang R, Xia M.   +7 more
europepmc   +1 more source

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial. [PDF]

Neurooncol Adv
Ozer BH, Cohen AL, Colman H, Penas-Prado M, de Groot J, Loghin ME, Pan E, Raizer JJ, Kumthekar P, Fink KL, Walbert T, Merrell RT, Groves MD, Ahluwalia MS, Wu J, Burton EC, Vera E, Mendoza T, Grajkowska E, Wall K, Reyes J, Yuan Y, Armstrong TS, Gilbert MR.   +23 more
europepmc   +1 more source

Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. [PDF]

Clin Med Insights Oncol
Zheng H, Wen F, Wu B.
europepmc   +1 more source

Retinal organoid screening reveals ABT-737 and luminespib as potential agents against a cone- precursor-derived subtype of retinoblastoma. [PDF]

Mol Ther Oncol
Kelk J, Rozanska A, Sotiriadou E, Astley D, Hussain R, Unsworth A, Gangar A, Robinson A, Queen R, Coxhead J, Steel DH, Armstrong L, Parulekar M, Hardcastle I, Veal GJ, Lako M.   +15 more
europepmc   +1 more source

SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma. [PDF]

J Exp Clin Cancer Res
Liu Z, Bagchi S, Yan C, Hu Y, Blum G, Ma A, Jin J, Luo M, Di Bella S, Verona F, Appella E, Giannini G, Thiele CJ, Veschi V.   +13 more
europepmc   +1 more source

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients

Neuro-Oncology, 2017
Christin Schmidt, Nil A. Schubert, S. Brabetz, Norman L Mack, B. Schwalm, J. Chan, F. Selt, C. Herold‐Mende, O. Witt, T. Milde, S. Pfister, A. Korshunov, M. Kool   +12 more
semanticscholar   +1 more source

Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform. [PDF]

J Cheminform
Xu S, Hu Y, Mangione W, Van Norden M, Elefteriou K, Falls Z, Samudrala R.   +6 more
europepmc   +1 more source

Integrated computational screening of FDA-approved anticancer drugs as novel HPV-16 E6 inhibitors in cervical cancer. [PDF]

Sci Rep
Ahmadi M, Yoosefian M.
europepmc   +1 more source